Article Versions Notes

Li Q, Ma L, Qiu B, Wen Y, Liang W, Hu W, Chen N, Zhang T, Xu S, Chen L, et al. Benefit from Adjuvant TKIs Versus TKIs Plus Chemotherapy in EGFR-Mutant Stage III-pN2 Lung Adenocarcinoma. Current Oncology. 2021; 28(2):1424-1436. https://doi.org/10.3390/curroncol28020135

Li, Qiwen, Li Ma, Bo Qiu, Yuzhi Wen, Wenhua Liang, Wanming Hu, Naibin Chen, Tian Zhang, Shuangbing Xu, Lingjuan Chen, and et al. 2021. "Benefit from Adjuvant TKIs Versus TKIs Plus Chemotherapy in EGFR-Mutant Stage III-pN2 Lung Adenocarcinoma" Current Oncology 28, no. 2: 1424-1436. https://doi.org/10.3390/curroncol28020135

Li, Q., Ma, L., Qiu, B., Wen, Y., Liang, W., Hu, W., Chen, N., Zhang, T., Xu, S., Chen, L., Guo, M., Zhao, Y., Liu, S., Guo, J., Wang, J., Wang, S., Wang, X., Pang, Q., Long, H., & Liu, H. (2021). Benefit from Adjuvant TKIs Versus TKIs Plus Chemotherapy in EGFR-Mutant Stage III-pN2 Lung Adenocarcinoma. Current Oncology, 28(2), 1424-1436. https://doi.org/10.3390/curroncol28020135